(D-Arg1,D-Trp7·9,Leu11)-Substance P

Research use only, not for human use.

Spantide I, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation.

Spantide antagonizes both bombesin & substance P. It is also tachykinin receptor antagonist.

———

Spantide I (50 and 100 nM perfused through the cerebral ventricles) causes a complete respiratory arrest in all of the examined animals.Spantide I (36 μg/mouse, ip daily) significantly decreases the number of perforated corneas, bacterial counts, and PMNs. Spantide I also downregulates the mRNA levels for type I cytokines (e.g., IFN-γ) as well as MIP-2, IL-6, TNF-α, and IL-1β.Animal Model:Female, 8-week-old C57BL/6 (B6) and BALB/c mice.Dosage:36 μg/mouse.Administration:IP on days -1 and 0 (day of infection) and daily through 5 days pi (post infection).Result:At 3 and 5 days pi, compound-treated mice had significantly less severe ocular disease than did the PBS-treated mice.Contained significantly fewer PMNs than the corneas of PBS-treated mice at 3 and 5 days pi.Significantly reduced levels of corneal TNF-α mRNA at 3 and 5 days pi.Significantly reduced the level of IL-18 mRNA at 1 day pi.

———

Others

Other Targets

———

———

———

91224-37-2

1497.82

C75H108N20O13

>98% (HPLC)

H2O : 100 mg/mL (66.77 mM; ultraphonic)

———

——

(-20℃)

With Ice Pack

≥ 2 years